Merck

Merck Secures Groundbreaking Deal for Obesity Drug in China Valued at Nearly $2 Billion

5 days ago

In a significant stride towards addressing the global obesity epidemic, pharmaceutical giant Merck has announced a landmark agreement with Chinese biopharmaceutical company, Eddingpharm. This deal, valued at nearly $2 billion, marks Merck’s strategic entry into the rapidly expanding weight-loss drug market in China. The partnership is expected to leverage the unique characteristics of both companies to improve patient outcomes in one of the world's largest markets for obesity treatment.

Merck Expands Cancer Drug Portfolio with $3.3 Billion Agreement in China

1 month ago

In a significant move to bolster its cancer treatment offerings, Merck & Co. has secured a lucrative agreement with a Chinese biotech company, attaching itself to a compelling late-stage cancer therapy. The deal, which could reach a staggering $3.3 billion, is centered around the promising drug known as sugemalimab, known for its potential effectiveness against various tumors.

Merck Adjusts Sales Forecast Amid Slowing Demand for Gardasil Vaccine in China

2 months ago

In a recent update, Merck & Co. has revised its sales outlook downward, largely attributed to subpar demand for its Gardasil vaccine in the Chinese market. The pharmaceutical giant is now bracing for a potential decline in sales as the uptake of their human papillomavirus (HPV) vaccine fails to meet projections.